Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
10
CRDF Quote, Financials, Valuation and Earnings
Last price:
$1.62
Seasonality move
:
-2.87%
Day range:
$1.55 - $1.65
52-week range:
$1.48 - $4.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
207.55x
P/B ratio:
2.25x
Volume:
406.4K
Avg. volume:
1.5M
1-year change:
-65.9%
Market cap:
$109.8M
Revenue:
$683K
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
$103.5K | -$0.20 | -26.61% | -8.42% | $10.25 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
INSP
Inspire Medical Systems, Inc.
|
$266.2M | $0.68 | 0.09% | -41.74% | $77.86 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
OM
Outset Medical, Inc.
|
$28.9M | -$0.68 | -4.03% | -79.94% | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
$1.63 | $10.25 | $109.8M | -- | $0.00 | 0% | 207.55x |
|
AGEN
Agenus, Inc.
|
$3.21 | $12.33 | $116M | -- | $0.00 | 0% | 0.81x |
|
CRIS
Curis, Inc.
|
$1.14 | $14.00 | $14.7M | -- | $0.00 | 0% | 1.09x |
|
INSP
Inspire Medical Systems, Inc.
|
$59.78 | $77.86 | $1.7B | 12.04x | $0.00 | 0% | 1.94x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
OM
Outset Medical, Inc.
|
$3.53 | $11.75 | $62.7M | -- | $0.00 | 0% | 0.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
2.03% | 2.141 | 0.73% | 4.14x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
INSP
Inspire Medical Systems, Inc.
|
3.95% | -0.889 | 1.22% | 4.47x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
OM
Outset Medical, Inc.
|
44.37% | 4.147 | 153.61% | 5.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
-$104K | -$12M | -79.44% | -81.17% | -9978.33% | -$10.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
INSP
Inspire Medical Systems, Inc.
|
$233M | $46.1M | 20.12% | 21.07% | 17.14% | $41.8M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
OM
Outset Medical, Inc.
|
$12.2M | -$17.3M | -33.49% | -65.77% | -60.07% | -$9.7M |
Cardiff Oncology, Inc. vs. Competitors
-
Which has Higher Returns CRDF or AGEN?
Agenus, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -116.82%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CRDF or AGEN?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 528.83%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 284.22%. Given that Cardiff Oncology, Inc. has higher upside potential than Agenus, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 AGENAgenus, Inc.2 1 0 -
Is CRDF or AGEN More Risky?
Cardiff Oncology, Inc. has a beta of 1.325, which suggesting that the stock is 32.539% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock CRDF or AGEN?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or AGEN?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 207.55x versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.207.55x -- $120K -$11.3M AGENAgenus, Inc.0.81x -- $30.2M $63.9M
-
Which has Higher Returns CRDF or CRIS?
Curis, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -243.36%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About CRDF or CRIS?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 528.83%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1128.07%. Given that Curis, Inc. has higher upside potential than Cardiff Oncology, Inc., analysts believe Curis, Inc. is more attractive than Cardiff Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 CRISCuris, Inc.4 0 0 -
Is CRDF or CRIS More Risky?
Cardiff Oncology, Inc. has a beta of 1.325, which suggesting that the stock is 32.539% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock CRDF or CRIS?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or CRIS?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 207.55x versus 1.09x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.207.55x -- $120K -$11.3M CRISCuris, Inc.1.09x -- $3.2M -$7.7M
-
Which has Higher Returns CRDF or INSP?
Inspire Medical Systems, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of 50.58%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Inspire Medical Systems, Inc.'s return on equity of 21.07%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M INSPInspire Medical Systems, Inc.86.6% $4.65 $813.3M -
What do Analysts Say About CRDF or INSP?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 528.83%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $77.86 which suggests that it could grow by 30.24%. Given that Cardiff Oncology, Inc. has higher upside potential than Inspire Medical Systems, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Inspire Medical Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 INSPInspire Medical Systems, Inc.4 12 0 -
Is CRDF or INSP More Risky?
Cardiff Oncology, Inc. has a beta of 1.325, which suggesting that the stock is 32.539% more volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.041%.
-
Which is a Better Dividend Stock CRDF or INSP?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or INSP?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $269.1M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Inspire Medical Systems, Inc.'s net income of $136.1M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Inspire Medical Systems, Inc.'s PE ratio is 12.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 207.55x versus 1.94x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.207.55x -- $120K -$11.3M INSPInspire Medical Systems, Inc.1.94x 12.04x $269.1M $136.1M
-
Which has Higher Returns CRDF or LADX?
LadRx Corp. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of --. Cardiff Oncology, Inc.'s return on equity of -81.17% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About CRDF or LADX?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 528.83%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Cardiff Oncology, Inc., analysts believe LadRx Corp. is more attractive than Cardiff Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 LADXLadRx Corp.0 0 0 -
Is CRDF or LADX More Risky?
Cardiff Oncology, Inc. has a beta of 1.325, which suggesting that the stock is 32.539% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock CRDF or LADX?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or LADX?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are larger than LadRx Corp. quarterly revenues of --. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 207.55x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.207.55x -- $120K -$11.3M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns CRDF or OM?
Outset Medical, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -67.5%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Outset Medical, Inc.'s return on equity of -65.77%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M OMOutset Medical, Inc.42.36% -$1.09 $228.2M -
What do Analysts Say About CRDF or OM?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 528.83%. On the other hand Outset Medical, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 232.86%. Given that Cardiff Oncology, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Outset Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 OMOutset Medical, Inc.3 0 0 -
Is CRDF or OM More Risky?
Cardiff Oncology, Inc. has a beta of 1.325, which suggesting that the stock is 32.539% more volatile than S&P 500. In comparison Outset Medical, Inc. has a beta of 2.079, suggesting its more volatile than the S&P 500 by 107.879%.
-
Which is a Better Dividend Stock CRDF or OM?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Outset Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or OM?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Outset Medical, Inc. quarterly revenues of $28.9M. Cardiff Oncology, Inc.'s net income of -$11.3M is higher than Outset Medical, Inc.'s net income of -$19.5M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Outset Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 207.55x versus 0.45x for Outset Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.207.55x -- $120K -$11.3M OMOutset Medical, Inc.0.45x -- $28.9M -$19.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
